Role of indomethacin in ductus closure

An update evaluation

S. M. Douidar, Carol Richardson, W. R. Snodgrass

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Patent ductus arteriosus (PDA) in premature infants is a current challenge to pediatricians. Pharmacological closure of PDA with indomethacin, a prostaglandin synthetase inhibitor is an effective drug therapy, along with usual medical treatment. Administration of indomethacin may decrease mortality and morbidity (e.g. bronchopulmonary dysplasia) among very small premature infants (<1,000 g). Co-administration of furosemide with indomethacin may lessen the transient renal side effects of indomethacin. The therapeutic efficacy of indomethacin in closure of PDA depends largely on understanding and manipulation of the pharmacokinetic characteristics of the drug in preterm infants. Maintaining a therapeutic level of the drug in plasma is essential to achieve an optimal therapeutic response. Compared to surgical ligation, indomethacin is a noninvasive, less expensive and safer therapy for ductus closure.

Original languageEnglish (US)
Pages (from-to)196-212
Number of pages17
JournalDevelopmental Pharmacology and Therapeutics
Volume11
Issue number4
StatePublished - 1988

Fingerprint

Indomethacin
Patent Ductus Arteriosus
Premature Infants
Therapeutics
Prostaglandin Antagonists
Bronchopulmonary Dysplasia
Furosemide
Prostaglandin-Endoperoxide Synthases
Pharmaceutical Preparations
Ligation
Pharmacokinetics
Pharmacology
Morbidity
Kidney
Drug Therapy
Mortality

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Role of indomethacin in ductus closure : An update evaluation. / Douidar, S. M.; Richardson, Carol; Snodgrass, W. R.

In: Developmental Pharmacology and Therapeutics, Vol. 11, No. 4, 1988, p. 196-212.

Research output: Contribution to journalArticle

@article{4be71612131849d2828f41414ab19502,
title = "Role of indomethacin in ductus closure: An update evaluation",
abstract = "Patent ductus arteriosus (PDA) in premature infants is a current challenge to pediatricians. Pharmacological closure of PDA with indomethacin, a prostaglandin synthetase inhibitor is an effective drug therapy, along with usual medical treatment. Administration of indomethacin may decrease mortality and morbidity (e.g. bronchopulmonary dysplasia) among very small premature infants (<1,000 g). Co-administration of furosemide with indomethacin may lessen the transient renal side effects of indomethacin. The therapeutic efficacy of indomethacin in closure of PDA depends largely on understanding and manipulation of the pharmacokinetic characteristics of the drug in preterm infants. Maintaining a therapeutic level of the drug in plasma is essential to achieve an optimal therapeutic response. Compared to surgical ligation, indomethacin is a noninvasive, less expensive and safer therapy for ductus closure.",
author = "Douidar, {S. M.} and Carol Richardson and Snodgrass, {W. R.}",
year = "1988",
language = "English (US)",
volume = "11",
pages = "196--212",
journal = "Developmental Pharmacology and Therapeutics",
issn = "0379-8305",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Role of indomethacin in ductus closure

T2 - An update evaluation

AU - Douidar, S. M.

AU - Richardson, Carol

AU - Snodgrass, W. R.

PY - 1988

Y1 - 1988

N2 - Patent ductus arteriosus (PDA) in premature infants is a current challenge to pediatricians. Pharmacological closure of PDA with indomethacin, a prostaglandin synthetase inhibitor is an effective drug therapy, along with usual medical treatment. Administration of indomethacin may decrease mortality and morbidity (e.g. bronchopulmonary dysplasia) among very small premature infants (<1,000 g). Co-administration of furosemide with indomethacin may lessen the transient renal side effects of indomethacin. The therapeutic efficacy of indomethacin in closure of PDA depends largely on understanding and manipulation of the pharmacokinetic characteristics of the drug in preterm infants. Maintaining a therapeutic level of the drug in plasma is essential to achieve an optimal therapeutic response. Compared to surgical ligation, indomethacin is a noninvasive, less expensive and safer therapy for ductus closure.

AB - Patent ductus arteriosus (PDA) in premature infants is a current challenge to pediatricians. Pharmacological closure of PDA with indomethacin, a prostaglandin synthetase inhibitor is an effective drug therapy, along with usual medical treatment. Administration of indomethacin may decrease mortality and morbidity (e.g. bronchopulmonary dysplasia) among very small premature infants (<1,000 g). Co-administration of furosemide with indomethacin may lessen the transient renal side effects of indomethacin. The therapeutic efficacy of indomethacin in closure of PDA depends largely on understanding and manipulation of the pharmacokinetic characteristics of the drug in preterm infants. Maintaining a therapeutic level of the drug in plasma is essential to achieve an optimal therapeutic response. Compared to surgical ligation, indomethacin is a noninvasive, less expensive and safer therapy for ductus closure.

UR - http://www.scopus.com/inward/record.url?scp=0023759276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023759276&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 196

EP - 212

JO - Developmental Pharmacology and Therapeutics

JF - Developmental Pharmacology and Therapeutics

SN - 0379-8305

IS - 4

ER -